Update: Johnson & Johnson Is A Stellar Company With Ample Upside
Summary We view Johnson & Johnson’s capital appreciation and dividend growth upside potential quite favorably. The top end of our fair value estimate range sits at $206 per share of JNJ. In this article, we cover Johnson & Johnson’s stellar financial performance, recent guidance boosts, and some of its legal hurdles. Johnson & Johnson announced on November 12 that it would spinoff its consumer-facing operations while retaining its medical devices and pharmaceutical operations. —- By Valuentum Analysts —– On October 19, Johnson & Johnson (JNJ) reported third-quarter earnings for fiscal 2021 (period ended October 3, 2021) that missed consensus top-line estimates but beat consensus bottom-line estimates. The healthcare giant also raised its full-year guidance (again) for fiscal 2021 as its ‘Pharmaceutical’ segment is growing at a … Read more